Medicare obesity treatment has become a crucial topic in the discussion about healthcare coverage for millions of Americans struggling with weight-related issues.Despite the demand for obesity medications like Wegovy and Zepbound, the Trump administration opted not to include these vital treatments in the Medicare program under Part D, leaving many without access to effective weight loss drugs.